Granahan Investment Management’s Apogee Therapeutics APGE Stock Holding History

Granahan Investment Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.5M	Sell	33,889 -41,197	-55%	-$3.71M	0.16%	122
2026 Q1	$6.32M	Sell	75,086 -19,634	-21%	-$1.43M	0.31%	84
2025 Q4	$7.15M	Sell	94,720 -37,680	-28%	-$2.37M	0.31%	75
2025 Q3	$5.26M	Buy	132,400 +1,262	+1%	+$48.2K	0.22%	93
2025 Q2	$5.7M	Buy	131,138 +22,798	+21%	+$867K	0.23%	93
2025 Q1	$4.05M	Buy	108,340 +15,486	+17%	+$599K	0.2%	108
2024 Q4	$4.21M	Buy	92,854 +1,097	+1%	+$55.9K	0.18%	117
2024 Q3	$5.39M	Buy	+91,757	New	+$4.4M	0.21%	121

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Granahan Investment Management's APGE Position: Q2 2026 in Review

Granahan Investment Management reduced its Apogee Therapeutics (APGE) stake by 55% in Q2 2026, selling an estimated $3.71M and leaving 33,889 shares worth $4.5M. The position accounts for 0.16% of the portfolio, ranked #122.

Granahan Investment Management first reported a position in APGE in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.15M in Q4 2025. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Granahan Investment Management held 33,889 shares of Apogee Therapeutics worth $4.5M as of Q2 2026.
Granahan Investment Management sold 41,197 Apogee Therapeutics shares in Q2 2026, an estimated $3.71M.
Apogee Therapeutics made up 0.16% of Granahan Investment Management's portfolio in Q2 2026, its #122 holding.
Granahan Investment Management first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 8 quarters since.
Granahan Investment Management's Apogee Therapeutics position peaked at $7.15M in Q4 2025.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Granahan Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.